Background and aims: The LISTEN trial (ClinicalTrial.gov accession: NCT01950884) is a phase IV 52 weeks double blind parallel randomized controlled trial that evaluated the effect of ezetimibe plus lifestyle and dietary intervention (eze) vs. lifestyle and dietary intervention alone (placebo) on progression and complications of non-alcoholic steatohepatitis (NASH) evaluated by liver histology. Methods and results: Forty patients with NASH ascertained by histology were randomly allocated on the two study groups and subjected to a follow-up of 52 weeks, when they underwent a second liver biopsy. Main composite end point (EP) was based on the histological improvement in the severity of NASH. Thirty patients completed the study, Eze treatment was not able to improve the primary EP in comparison with placebo, with and odds ratio of 1.029 (0.18–6.38), p = 0.974. Treatment emergent adverse events registered during the study were not more prevalent in the treatment arm. Conclusions: ezetimibe administered on top of lifestyle and dietary modification failed to improve the histology of NASH in comparison with lifestyle and dietary modification alone. Trial accession number: ClinicalTrial.gov: NCT01950884.

Noto D., Petta S., Giammanco A., Spina R., Cabibi D., Porcasi R., et al. (2022). Lifestyle versus ezetimibe plus lifestyle in patients with biopsy-proven non-alcoholic steatohepatitis (LISTEN): A double-blind randomised placebo-controlled trial. NMCD. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES [10.1016/j.numecd.2022.01.024].

Lifestyle versus ezetimibe plus lifestyle in patients with biopsy-proven non-alcoholic steatohepatitis (LISTEN): A double-blind randomised placebo-controlled trial

Noto D.
Primo
Writing – Original Draft Preparation
;
Petta S.
Data Curation
;
Giammanco A.
Investigation
;
Spina R.
Membro del Collaboration Group
;
Cabibi D.
Membro del Collaboration Group
;
Porcasi R.
Membro del Collaboration Group
;
Caldarella R.
Membro del Collaboration Group
;
Ciaccio M.
Membro del Collaboration Group
;
Muratore R.
Membro del Collaboration Group
;
Cefalu A. B.
Membro del Collaboration Group
;
Craxi A.
Conceptualization
;
Averna M.
Ultimo
Methodology
2022

Abstract

Background and aims: The LISTEN trial (ClinicalTrial.gov accession: NCT01950884) is a phase IV 52 weeks double blind parallel randomized controlled trial that evaluated the effect of ezetimibe plus lifestyle and dietary intervention (eze) vs. lifestyle and dietary intervention alone (placebo) on progression and complications of non-alcoholic steatohepatitis (NASH) evaluated by liver histology. Methods and results: Forty patients with NASH ascertained by histology were randomly allocated on the two study groups and subjected to a follow-up of 52 weeks, when they underwent a second liver biopsy. Main composite end point (EP) was based on the histological improvement in the severity of NASH. Thirty patients completed the study, Eze treatment was not able to improve the primary EP in comparison with placebo, with and odds ratio of 1.029 (0.18–6.38), p = 0.974. Treatment emergent adverse events registered during the study were not more prevalent in the treatment arm. Conclusions: ezetimibe administered on top of lifestyle and dietary modification failed to improve the histology of NASH in comparison with lifestyle and dietary modification alone. Trial accession number: ClinicalTrial.gov: NCT01950884.
Settore MED/09 - Medicina Interna
Settore MED/12 - Gastroenterologia
Noto D., Petta S., Giammanco A., Spina R., Cabibi D., Porcasi R., et al. (2022). Lifestyle versus ezetimibe plus lifestyle in patients with biopsy-proven non-alcoholic steatohepatitis (LISTEN): A double-blind randomised placebo-controlled trial. NMCD. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES [10.1016/j.numecd.2022.01.024].
File in questo prodotto:
File Dimensione Formato  
Lifestyle versus ezetimibe plus lifestyle in patients with biopsy.pdf

non disponibili

Descrizione: Articolo Principale
Tipologia: Versione Editoriale
Dimensione 378.86 kB
Formato Adobe PDF
378.86 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10447/544471
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? ND
social impact